5 ESSENTIAL ELEMENTS FOR MOUSE

All enrolled sufferers who been given no less than 1 dose of zosuquidar or placebo through induction were monitored to the incidence of adverse situations (439 individuals, 219 on zosuquidar and 210 on placebo). The commonest adverse activities ended up relevant to the duration of extended and sizeable myelosuppression as is expected with induction